[1] Kang DJ, Betrapally NS, Ghosh SA, et al. Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice. Hepatology,2016,64:1232-1248.
[2] Ahluwalia V, Betrapally NS, Hylemon PB, et al. Impaired gut-liver-brain axis in patients with cirrhosis. Sci Rep,2016,6:26800.
[3] Riggio O, Mannaioni G, Ridola L, et al. Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: a study on the pathophysiology of hepatic encephalopathy. Am J Gastroenterol,2010,105:1374-1381.
[4] Montagnese S, Biancardi A, Schiff S, et al. Different biochemical correlates for different neuropsychiatric abnormalities in patients with cirrhosis. Hepatology,2011,53:558-566.
[5] Shawcross DL, Sharifi Y, Canavan JB, et al. Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol,2011,54:640-649.
[6] Butterworth RF. The liver-brain axis in liver failure: neuroinflammation and encephalopathy. Nat Rev Gastroenterol Hepatol,2013,10:522-528.
[7] Zemtsova I, Gorg B, Keitel V, et al. Microglia activation in hepatic encephalopathy in rats and humans. Hepatology,2011,54:204-215.
[8] Rothhammer V, Borucki DM, Tjon EC, et al. Microglial control of astrocytes in response to microbial metabolites. Nature,2018,557:724-728.
[9] Shah A, Shanahan E, Macdonald GA, et al. Systematic review and meta-analysis: prevalence of small intestinal bacterial overgrowth in chronic liver disease. Semin Liver Dis,2017,37:388-400.
[10] Gupta A, Dhiman RK, Kumari S, et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol,2010,53:849-855.
[11] Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol,2014,60:197-209.
[12] Wang Q, Wang B, Saxena V, et al. The gut-liver axis: impact of a mouse model of small-bowel bacterial overgrowth. J Surg Res,2018,221:246-256.
[13] Teltschik Z, Wiest R, Beisner J, et al. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. Hepatology,2012,55:1154-1163.
[14] Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature,2014,509:183-188.
[15] McMillin M, Frampton G, Grant S, et al. Bile acid-mediated sphingosine-1-phosphate receptor 2 signaling promotes neuroinflammation during hepatic encephalopathy in mice. Front Cell Neurosci,2017,11:191.
[16] Arab JP, Karpen SJ, Dawson PA, et al. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology,2017,65:350-362.
[17] Parseus A, Sommer N, Sommer F, et al. Microbiota-induced obesity requires farnesoid X receptor. Gut,2017,66:429-437.
[18] Gluud LL, Vilstrup H, Morgan MY. Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysis. Hepatology,2016,64:908-922.
[19] Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American association for the study of liver diseases and the european association for the study of the liver. Hepatology,2014,60:715-735.
[20] Lunia MK, Sharma BC, Sharma P, et al. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol,2014,12:1003-1008 e1001.
[21] Kang SH, Lee YB, Lee JH, et al. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. Aliment Pharmacol Ther,2017,46:845-855.
[22] Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther,2016,43 Suppl 1:11-26. |
